Assessing the size of the US recall issue
This article was originally published in Clinica
Executive Summary
With the US in mid-regulatory review, stakeholders are keenly pushing for a safer and faster system, but there are different views on how to achieve those goals. That was shown at last week’s US senate special committee on ageing (www.clinica.co.uk April 14 2011, Risk averse US needs to address device processes). The differing views also extend to the magnitude of the recall problem in the US.